Chronic obstructive pulmonary disease (COPD) and lung cancer are linked diseases, with both the incidence of and risk of death from non-small cell lung cancer being increased by the presence of COPD. Despite numerous well-performed epidemiological studies having described this link over the past 30 years, the operative mechanisms remain elusive. One of the major obstacles to advancement in the field has been the lack of patient cohorts that have been phenotyped for both COPD and lung cancer. This review discusses several studies performed over the past few years highlighting the impact of COPD on the outcomes of patients with non-small cell lung cancer with respect to lung cancer screening, immune-based therapies, and lung cancer chemoprevention.
Cigarette smoking is the leading cause of preventable death worldwide, accounting for approximately six million deaths annually (1) . Although effective therapies exist for some cigarette smoke-induced diseases (e.g., coronary artery disease), this does not hold true for chronic obstructive pulmonary disease (COPD) and non-small cell lung cancer (NSCLC). The disease burden attributable to these two diseases is not trivial-COPD is the third leading cause of death in the United States, and lung cancer is the leading cause of cancer death worldwide (2, 3) . Given the prevalence of COPD and lung cancer, it is not surprising that both diseases frequently occur within the same individual. However, several wellperformed epidemiological studies have demonstrated that COPD and lung cancer are linked, with COPD patients displaying a higher incidence of lung cancer than patients without obstructive lung disease (4) . Furthermore, this link is independent of cigarette smoke consumption, strongly suggesting that there exist common mechanisms linking COPD/emphysema and lung cancer. Although the exact nature of the mechanistic link between COPD and lung cancer remains obscure, several recent studies have shed light on shared mechanisms between the two diseases (5-7), which are discussed in detail in this review.
COPD Increases Lung Cancer Incidence and Death
Several epidemiological studies have identified an association between the presence of airflow obstruction and the incidence of and risk of death from lung cancer (5, (8) (9) (10) (11) (12) (13) . The relative contribution of emphysema versus airflow obstruction remains unclear, though both are likely to play a role ( Table 1 ). As such, there are studies that clearly identify both the presence and the severity of radiographic emphysema and airflow limitation as risk factors for lung cancer incidence and death (10) (11) (12) (13) .
The presence of COPD and emphysema has a new practical application in the era of computed tomographic (CT) screening for lung cancer. Results of the National Lung Screening Trial have essentially ushered in the era of CT screening for lung cancer because the study demonstrated a 20% reduction in risk of lung cancer death (14) . Young and colleagues reanalyzed the National Lung Screening Trial dataset in an attempt to show the predictive value of the presence of COPD and radiographic incidence in this cohort (5) . Notably, patients with COPD were twice as likely to be diagnosed with lung cancer during the screening process as otherwise matched patients without COPD. Furthermore, the COPD group was essentially devoid of premalignant lesions (e.g., adenocarcinoma in situ), suggesting that the presence of COPD nurtures the progression to invasive adenocarcinoma formation versus the persistence of immature lesions. This study supports the notion that all subjects with COPD and/or radiographic emphysema should be candidates for lung cancer screening. This is a relevant issue because just approximately 4% of screen-eligible subjects actually undergo CT screening (15) . This is at least in part due to the complicated eligibility criteria (age .55 yr, .30 pack-years, quit ,15 yr prior). Adjusting the eligibility criteria to include a diagnosis of COPD would ensure that subjects at particularly high risk for lung cancer are referred for lung cancer screening. It is also likely that the presence of airflow obstruction and radiographic emphysema will feature in novel risk prediction models for pulmonary nodule management, many of which are currently under construction.
Are COPD/Emphysema and Lung Cancer Polar Opposites?
At first glance, emphysema and lung cancer feature pathogenic features on opposite ends of the spectrum. For example, apoptosis is a prominent feature of emphysema, with alveolar cell death serving as a gateway to airspace enlargement. In contrast, apoptosis is a rare (but desired) event in lung cancer, which is characterized by the avoidance of apoptosis and the presence of undeterred cellular proliferation. Similarly, cancers prominently feature angiogenesis, whereas alveolar capillary dropout is frequently encountered in COPD/emphysema. However, when considered from a "cell at risk" perspective, it is easier to comprehend how the emphysematous microenvironment would nurture lung cancer development. In this context, the alveolar capillary dropout and poor vascular supply may induce the expression of genes such as hypoxiainducible factor-1a, which is typically expressed only by invasive cancers. Similarly, cells residing in fields at risk frequently display evidence of genetic mutation in key genes such as TP53 and CDK2N2A (16, 17) . If these cells resided within an emphysematous microenvironment, apoptotic pressure would be high. However, these cells may lack the ability to undergo apoptosis, given their underlying genetic abnormalities, and would therefore be at particularly high risk for malignant transformation.
Immune Responses in COPD and Lung Cancer
Several recent studies have attempted to determine the immune cell composition and function in NSCLC, and a few of these included immune profiling of the lung tissue in these patients. Because COPD is frequently encountered in patients with NSCLC (approximately 70%), the ability to assess the role of COPD in immune response is possible. Although the accumulation of inflammatory cells such as neutrophils and alveolar macrophages has long been known to occur in COPD, these (18) . In addition, there is strong evidence from mouse models of lung cancer that IL-17 drives a protumor inflammatory response and fuels lung tumor growth (19) . However, it is unclear if Th17-driven inflammation occurs only in the setting of active cigarette smoking, because one study was able to identify increases in Th17 content only by smoking status and not by disease severity (6) . There is also evidence that CD8
1 T-cell status is impacted by COPD and that PD1 (programmed cell death 1)-expressing populations are associated with disease progression (7) .
The immune cell composition present in NSCLC specimens is quite heterogeneous and is different in lung adenocarcinomas as opposed to lung squamous cell carcinomas. Myeloid lineage cells are the most prevalent immune cell populations in NSCLC, with neutrophils being slightly more common than macrophages. Similar to COPD immune cell composition, CD4
1 cellular differentiation drives unique subphenotypes in NSCLC, with some cases displaying Th1 predominance and others displaying enhanced Treg immunity. Our group identified a strong inverse correlation between neutrophil (defined as CD66b 1 ) content and CD8
1 T-cell content (20) . None of the other myeloid populations displayed this feature, nor did the neutrophils in adjacent lung tissue. Notably, this observation was validated by an independent study (21) . Additional data to support a deleterious role for neutrophils in NSCLC come from the Alizadeh group that introduced "CIBERSORT," a method for estimating the cellular content of multicellular tissues using their gene expression profiles (22) . Alizadeh and colleagues analyzed microarray gene expression data from more than 18,000 patients spanning 30 cancer types to infer the immune cell content using novel cell type-specific gene expression profiles. They found that neutrophil content predicted mortality better than any other immune cell populations across all cancer types and specifically in lung adenocarcinoma (23) . Using a unique cohort of 73 patients with NSCLC, 50 of whom had COPD, my colleagues and I assessed the relationships between COPD immune cell content (nonadjacent lung tissue) and NSCLC immune cell content within matched cases. Correlation of immune cell composition between the two diseases correlated most strongly for the CD4 1 subsets, specifically Th1 cells (6) . In other words, patients with COPD displaying robust Th1-mediated immunity within COPD-affected lung tissue harbored lung cancers that were heavily infiltrated with Th1 cells. Biton and colleagues used a different approach, leveraging formalin-fixed, paraffinembedded tissues from patients with NSCLC both with and without COPD to show that patients with COPD displayed enhanced PD1 and TIM3 (T-cell immunoglobulin mucin 3) staining on the CD8
1 cellular population (7). Thus, immune activity and exhaustion both appear to be enhanced in patients with COPD who have NSCLC compared with no-COPD control subjects.
Impact of COPD on Immunotherapy for NSCLC
As highlighted in the introductory text above, a diagnosis of COPD leads to increased mortality from lung cancer, such that life survival curves demonstrated reduced survival for patients with NSCLC with COPD compared with those without COPD. Somewhat counterintuitively, cigarette smoking consumption predicts favorable anti-PD1 treatment responses, though this is likely related to increased mutational spectral burden and tumor neoantigen load (24) . Surprisingly, two recent studies reported increased survival in anti-PD1 recipient patients with NSCLC with COPD versus those without (6, 7) . This represents a highly intriguing and unexpected finding because the survival curves have actually flipped, with the presence COPD favoring survival. Although one of the studies involved relatively small cohorts, the total number of patients between the two studies involved more than 150 patients in each arm (COPD vs. no COPD). The mechanism underlying these findings remains unknown, though the presence of enhance Th1 immunity in a subset of patients with COPD may be responsible because the existence of the "interferon-g signature" has recently been shown to predict favorable anti-PD1 treatment responses (25) . Alternatively, the enhanced expression of the inhibitory receptors PD1 and TIM3 by tumorinfiltrating CD8
1 T cells may be the cause of improved anti-PD1 treatment responses (see Figure 1) . Prospective studies will be required to validate the presence of COPD as a predictor of favorable treatment response to immune checkpoint blockade and to address the mechanisms by which this occurs.
Therapeutic Goal: Identify a COPD Agent that Doubles as a Lung Cancer Chemopreventive
When considering an exhaustive study of a potential therapeutic target for patients with COPD, it is imperative that the investigative team consider the impact of such a therapeutic on lung cancer pathogenesis. Although a particular target may hold promise as a COPD therapeutic, if this strategy would promote tumorigenesis, then subclinical lesions might develop into invasive cancers. Matrix metalloproteinase 12 (MMP-12 or macrophage elastase) serves as an excellent example in this regard. Extensive preclinical and clinical data support a deleterious role for MMP-12 in the progression of COPD and emphysema, including the fact that it is one of the most highly induced genes in patients with COPD (26, 27) . Developing antagonists against MMP-12 would be a logical therapeutic strategy for COPD/emphysema. Unfortunately, MMP-12 is one of the rare prohost MMPs with respect to tumorigenesis. MMP-12 generates angiostatic peptides from matrix protein precursors (28, 29) . In other words, MMP-12 inhibition in patients with COPD would likely slow the progression of COPD at the expense of speeding up the progression of lung cancer.
Because the majority of lung cancerassociated mortality resides within the COPD populations (.20 million patients in the United States), the clear goal of the field should be to develop a disease-modifying therapy for COPD that also functions as a lung cancer chemopreventive. Although this may be a lofty goal (disease-modifying therapies for COPD do not exist), the existence of potential therapeutic targets TIM3 TIM3 PD1 PD1 Figure 1 . Proposed mechanisms of improved anti-PD1 treatment outcomes in COPD. In the setting of COPD, CD4 1 cellular differentiation is skewed toward the IFN-g-producing Th1 phenotype. IFN-g release induces production of IFN-g-inducible genes, such as CXCL-9, -10, and -11. These proteins function to recruit additional lymphocytes to sites of tumorigenesis. In the setting of COPD, CD8
1 T cells display increased expression of the inhibitory receptors PD1 and TIM3, which also represent T-cell activation. In this setting, in which PDL1 expression is also enhanced, the stage is set for a favorable treatment response when anti-PD1 antibodies are administered, given that the tumor is rich in IFN-g and activated CD8
1 T cells. CD = cluster of differentiation; COPD = chronic obstructive pulmonary disease; CXCL = chemokine (C-X-C motif) ligand; IFN = interferon; PD1 = programmed cell death 1; PDL1 = programmed cell death ligand 1; Th1 = T-helper type cell type 1; TIM3 = T-cell immunoglobulin mucin 3.
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that drive COPD progression and lung cancer growth makes this theoretically possible. Many of the potential therapeutic targets in this regard involve the proinflammatory nature of both diseases, such as IL-6 and tumor necrosis factor-a, which have been shown to drive disease pathogenesis in relevant mouse models. One of the most attractive candidates is IL-1a/b, for which there are data to support deleterious roles in both COPD and lung cancer (30, 31) . A recent study using canakinumab, an IL-1b antagonist, serves as an inadvertent proof of concept in this regard (32) (33) (34) .
Canakinumab was recently studied in a group at high risk for cardiac events because there was ample preclinical data suggesting that IL-1b blockade would limit atherosclerotic disease. Therefore, more than 10,000 subjects with prior cardiac events and elevated C-reactive protein levels were randomized to receive either placebo or one of three doses of canakinumab. The primary endpoint was a recurrent cardiac event. The initial report of this study was somewhat inconclusive because only the middle dose of canakinumab tested was able to reduce subsequent cardiac events (35) . However, as described in a follow-up report, the investigative team found that the subsequent development of lung cancer incidence and death was reduced in a dosedependent manner (32) . Notably, only lung cancer incidence was affected, with the incidence of nonlung cancer being unchanged. These results strongly suggest that inhibiting IL-1b specifically in the lung is able to impact tumorigenesis, which would be consistent with the concept that the proinflammatory COPD disease environment promotes tumor formation. Although COPD status was not tracked in this cohort, given the age and smoking demographics of the cohort, it is likely that more than 50% of these subjects harbored the disease. Additional controlled studies will be required to prove the efficacy of IL-1b in this regard. Currently, canakinumab is being tested in combination with anti-PD1 antibody therapy for the treatment of NSCLC.
Conclusions
COPD and lung cancer are linked diseases, with the incidence and risk of death from lung cancer increased by the presence of COPD. This link has a new practical application, which lies in the recognition that patients with COPD are at particularly high risk for the subsequent development of lung cancer. This knowledge should lead to the addition of COPD diagnosis to prioritize patients to undergo potentially lifesaving CT screening for lung cancer. Although the exact nature of the link(s) between COPD and lung cancer remain difficult to elucidate, the interrelationships of immune system function in the two diseases are beginning to take shape. Enhanced Th1-mediated immunity and CD8
1 cellular activation (PD1 and TIM3 expression) in patients with COPD harboring lung cancer may explain why patients with COPD surprisingly display prolonged survival with administration of immune checkpoint inhibitor therapy. Last, the recent report that an IL-1b antagonist (canakinumab) was capable of reducing lung cancer development in high-risk patients serves as an important proof of concept that lung cancer chemoprevention is a viable strategy to combat the high morbidity and mortality associated with lung cancer in patients with COPD. n
